Real-world comparative outcomes of darolutamide- versus abiraterone-based triplet therapy for metastatic hormone-sensitive prostate cancer: a retrospective cohort study

Background: Triplet therapy with androgen deprivation therapy (ADT), docetaxel, and androgen receptor pathway inhibitors (ARPIs), either darolutamide or abiraterone, is one of the standard treatments for metastatic hormone-sensitive prostate cancer (mHSPC); however, no randomized trial has directly...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	I-Hsuan Alan Chen, Ren-In Chang, Chia-Cheng Yu, Tzu-Ping Lin, Chih-Yu Yang
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	SAGE Publishing 2026-07-01
Sarja:	Therapeutic Advances in Urology
Linkit:	https://doi.org/10.1177/17562872261463076
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!